Amgen's Bone Drug Xgeva Delays Pain From Prostate Cancer Metastases
This article was originally published in The Pink Sheet Daily
Executive Summary
Some physicians may be concerned by the incidence of osteonecrosis of the jaw reported in pivotal hormone-resistant prostate cancer trial.
You may also be interested in...
Xgeva Rejection Shows What’s Needed For Non-Metastatic CRPC Approvals
As expected, FDA rejected the new indication for Amgen’s bone drug Xgeva in prevention of bone metastases. But the door is still open for other therapies for castration resistant prostate cancer to target earlier stages of disease.
Positive Data On Bayer/Algeta's Alpharadin Could Accelerate Filing Timeline
Phase III trial studying the targeted radium alpha pharmaceutical in prostate cancer patients was halted early based on positive survival results.
Positive Data On Bayer/Algeta's Alpharadin Could Accelerate Filing Timeline
Phase III trial studying the targeted radium alpha pharmaceutical in prostate cancer patients was halted early based on positive survival results.